Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

CompletedOBSERVATIONAL

Enrollment

618

Participants

Timeline

Start Date

October 2, 2021

Primary Completion Date

January 27, 2022

Study Completion Date

January 27, 2022

Conditions

Melanoma

Interventions

DRUG

Nivolumab

Patients receiving nivolumab

DRUG

Ipilimumab + nivolumab

Patients receiving ipilimumab + nivolumab

DRUG

Pembrolizumab

Patients receiving pembrolizumab

DRUG

Dabrafenib + trametinib

Trial Locations (1)

Novartis Pharmaceuticals, East Hanover